Loading...
Galectin Therapeutics Inc.
GALT•NASDAQ
Healthcare
Biotechnology
$3.60
$0.30(9.09%)
Galectin Therapeutics Inc. (GALT) Financial Performance & Income Statement Overview
Review Galectin Therapeutics Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-11.45%
↓ 11.45%
Net Income Growth
-14.56%
↓ 14.56%
Operating Cash Flow Growth
-26.70%
↓ 26.70%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
46.15%
↑ 46.15%
ROIC
32.36%
↑ 32.36%
Galectin Therapeutics Inc. (GALT) Income Statement & Financial Overview
Review Galectin Therapeutics Inc.'s (GALT) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $9000.00 | $9000.00 |
| Gross Profit | $0.00 | $0.00 | -$9000.00 | -$9000.00 |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $11.11M | $7.59M | $9.81M | $8.05M |
| SG&A Expenses | $1.32M | $1.47M | $1.48M | $1.59M |
| Operating Expenses | $12.43M | $9.07M | $11.29M | $9.65M |
| Total Costs & Expenses | $12.43M | $9.07M | $11.29M | $9.65M |
| Interest Income | $84000.00 | $93000.00 | $80000.00 | $80000.00 |
| Interest Expense | $1.73M | $1.49M | $1.27M | $1.05M |
| Depreciation & Amortization | $10000.00 | $9000.00 | $9000.00 | $9000.00 |
| EBITDA | -$10.23M | -$9.72M | -$11.09M | -$10.43M |
| EBITDA Ratio | ||||
| Operating Income | -$12.43M | -$9.07M | -$11.29M | -$9.65M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $461000.00 | -$2.15M | -$1.08M | -$1.84M |
| Income Before Tax | -$11.97M | -$11.22M | -$12.37M | -$11.49M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$11.97M | -$11.22M | -$12.37M | -$11.49M |
| Net Income Ratio | ||||
| EPS | -$0.19 | -$0.18 | -$0.20 | -$0.19 |
| Diluted EPS | -$0.19 | -$0.18 | -$0.20 | -$0.19 |
| Weighted Avg Shares Outstanding | $62.31M | $62.28M | $62.23M | $61.98M |
| Weighted Avg Shares Outstanding (Diluted) | $62.31M | $62.28M | $62.23M | $61.98M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan